MRFR Year End Sale
Stem Cell Banking Market Research Report - Forecast till 2030

Stem Cell Banking Market Research Report: By Cell Type (Umbilical Cord Stem Cells, Adult Stem Cells, Embryonic Stem Cells), Bank Type (Private Banks, Public Banks, Hybrid Banks) and Application (Thalassemia, Cerebral Palsy, Diabetes, Leukemia, Autism) - Forecast to 2030

ID: MRFR/HC/6969-HCR | December 2022 | Region: Global | 90 Pages         

Stem Cell Banking Market

The Stem Cell Banking Market is expected to hold a value of USD 16.3 Billion by 2030 at CAGR of 15.10% during the forecast period 2022-2030

Segmentation

By Type Umbilical Cord Stem Cells Adult Stem Cells Embryonic Stem Cells
By Bank Type Private Banks Public Banks Hybrid Banks
By Application Thalassemia Cerebral Palsy Diabetes Leukemia Autism

Key Players

  • CBR Systems Inc. (US)
  • Cryo-Cell International Inc. (US)
  • Cordlife (Singapore)
  • Cryo-Save AG (Netherlands)
  • Global Cord Blood Corporation (Hong Kong)
  • Americord Registry LLC (US)
  • Smart Cells International Ltd. (UK)
  • Celgene Corporation (US)
  • BrainStorm Cell Therapeutics (US)
  • Regrow Biosciences Pvt. Ltd. (India)

Drivers

  • Worldwide surging newborn population
  • Growing awareness about stem cell therapeutics
  • Mounting development of novel technologies for stem cell preservation
  • processing
  • and storage
Speak to Analyst Request a Free Sample

Stem Cell Banking Market Forecast and Overview


Stem Cell Banking Market is expected to hold a value of USD 16.3 Billion by 2030 at 15.10% CAGR during the forecast period 2022-2030. Worldwide rising incidence of life-threatening genetic disorders and chronic diseases is expected to foster stem cell banking market growth during the forecast period. According to the statistics published by Genetics Home Reference, about one in 200,000 individuals in the US are born with syndrome A every year. An estimated 15,000 infants with syndrome B were born in 2021 across the world. In addition, about six in 10 adults in the US have a chronic disease, and four in 10 adults in the US have two or more chronic diseases.


Stem Cell Banking Market Influencer


Increased spending on the chronic diseases management is likely to act as a promising factor for stem cell banking market growth in the near future. The Centers for Disease Control and Prevention (CDC) reported that in the US, USD 3.3 trillion (90% of the total health expenditure) was spent on chronic and mental health conditions in 2021.


Market Drivers



  • Worldwide surging newborn population

  • Growing awareness about stem cell therapy

  • Mounting development of novel technologies for stem cell preservation, processing, and storage

  • Increasing mergers and acquisitions by prominent players in the stem cell banking market. For instance, in June 2021, AMAG Pharmaceuticals, Inc. entered into a definitive agreement to divest Cord Blood Registry to GI Partners, a San Francisco-based private equity investment firm, to extend the combined GI Partners’ capabilities internationally

  • Rising investments in stem cell research


Market Restraints



  • High operational and storage costs

  • Lack of awareness about stem cell banking in developing and underdeveloped countries


Stem Cell Banking Market Segmentation


By Cell Type




  • Umbilical Cord Stem Cells: Expected to command the market owing to the higher adoption of umbilical cord stem cells to treat around 80 diseases. This segment has been additionally classified into cord blood, cord tissue, and placenta. Worldwide growth in the number of placental and cord banks (particularly in the US and Europe) along with rising awareness about the therapeutic potential of stem cells is likely to support the considerable growth of the placenta segment.




  • Adult Stem Cells: Adult stem cells originate from adult tissue and redevelop into all the cell types of the organ from the origin.




  • Embryonic Stem Cells: Embryonic stem cells or pluripotent stem cells are produced from the inner cell mass of a blastocyst (embryo)




By Bank Type




  • Private Banks: This is anticipated to be the largest segment attributed to higher revenue generation from the superior service offering




  • Public Banks: Public cord blood banking is the act of donating the baby's cord blood to be used by a family in need. The cost of preserving cord blood is free at public banks.




  • Hybrid Banks: Few private cord blood banks also operate a public donation program where costs for these programs are mostly covered in part by the private side of the business. These banks are called hybrid banks.




By Application




  • Thalassemia: Expected to witness modest stem cell banking market growth.




  • Cerebral Palsy: Likely to hold the highest revenue share from 2019 to 2025 due to rising clinical and research applications of stem cell banking. In 2010, Dr. Kurtzberg conducted first trial on the safety and feasibility of cord blood for the treatment of acquired neurological disorders such as cerebral palsy.




  • Diabetes: Stem cell treatment can be used for both type 1 and type 2 diabetes and prevent diabetes-related complications such as heart disease, blindness, kidney failure and amputation of limbs.




  • Leukemia: A stem cell transplant can be used to restore healthy bone marrow in patients with leukemia. Stem cells help stimulate new bone marrow growth and restore the immune system.




  • Autism: In June 2014, Duke University Medicine was awarded USD 15 million to support an innovative research program to explore the use of umbilical cord blood cells to treat autism, stroke, cerebral palsy, and related brain disorders. On the contrary, the US Food and Drug Administration (FDA) has approved the use of stem cells for blood disorders, including cancer, but not for autism currently.




  • Others: This segment comprises acquired hearing loss, stroke, brain disorders, sickle cell disease, heart diseases, multiple sclerosis, Alzheimer's disease, Wiskott-Aldrich syndrome, etc.




By Region




  • Americas: The largest regional market. The presence of major stem cell banking market participants in the US, ongoing approval of stem cell lines for disease treatment, and increasing awareness among citizens about stem cell banking is about to nourish the dominance of the Americas throughout the forecast period.




  • Europe: The presence of initiatives implemented by the European Union and various organizations would augment the demand for cord blood banking. Furthermore, uniform regulations implemented by the European government about the support of voluntary and free donations, procedures to standardize the testing of donated tissues and cells, and procedures to ensure document safety and traceability would support the regional stem cell banking market growth over the study period.




  • Asia-Pacific: This region is anticipated to register comparatively higher CAGR over the assessment period attributed to rapidly developing medical infrastructure, growing older population along with as surge in prevalence of chronic diseases, and rising per capita healthcare expenditure in India, China, and Japan.




  • Middle East & Africa: The smallest market due to limited healthcare infrastructure and limited exposure to technological advancements.




Stem Cell Banking Market Key Players



  • CBR Systems, Inc. (US)

  • Cryo-Cell International, Inc. (US)

  • Cordlife (Singapore)

  • Cryo-Save AG (Netherlands)

  • Global Cord Blood Corporation (Hong Kong)

  • Americord Registry LLC (US)

  • Smart Cells International Ltd. (UK)

  • Celgene Corporation (US)

  • BrainStorm Cell Therapeutics (US)

  • Regrow Biosciences Pvt. Ltd. (India)



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 16.3 Billion
  CAGR   15.10%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Cell Type, Bank Type, Application
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   CBR Systems, Inc. (US), Cryo-Cell International, Inc. (US), Cordlife (Singapore), Cryo-Save AG (Netherlands), Global Cord Blood Corporation (Hong Kong), Americord Registry LLC (US), Smart Cells International Ltd. (UK), Celgene Corporation (US), BrainStorm Cell Therapeutics (US), Regrow Biosciences Pvt. Ltd. (India)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers

  • Worldwide surging newborn population
  • Growing awareness about stem cell therapeutics
  • Mounting development of novel technologies for stem cell preservation, processing, and storage
  • Increasing mergers and acquisitions by prominent players in the market.
  • Rising investments in stem cell research


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The valuation of the global stem cell market is estimated to reach USD USD 16.3 BN by 2030.

    CBR Systems, Inc. (US), Cryo-Cell International, Inc. (US), Cordlife (Singapore), Global Cord Blood Corporation (Hong Kong), Cryo-Save AG (Netherlands), Americord Registry LLC (US), Celgene Corporation (US), Smart Cells International Ltd. (UK), BrainStorm Cell Therapeutics (US), and Regrow Biosciences Pvt. Ltd. (India), are some of the major players operating in the stem cell market.

    Stem cells (SC) are a class of undifferentiated biological cells of a multicellular organism that have the ability to produce indefinite cells of the same type, from which certain types of cells (proliferation and replication) can be produced by differentiation in the body through early life and growth.

    The global stem cell market is projected to grow at approximately 15.10% CAGR during the forecast period (2022-2030).

    Increasing investment by major companies in stem cell research & development (R&D).

    North America holds the largest share in the global stem cell market, followed by Europe and the Asia Pacific, respectively.

    By application, the stem cell banking market has been bifurcated into thalassemia, cerebral palsy, diabetes, leukemia, autism, and others. The diabetes segment is likely to witness the fastest market growth due to the rising burden of diabetes mellitus (DM) across the world, thereby augmenting the demand for stem cells.